Media Release: Clarity Pharmaceuticals bolsters IP position through assignment of patents from the University of Melbourne

Sydney, Australia 16 February 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully completed the assignment of its key patent portfolio from the University of Melbourne. The assignment from the University of Melbourne to Clarity provides Clarity with the full rights and ownership of the patents moving forward.

Clarity previously held exclusive licenses on several granted patents and patent applications from the University of Melbourne. With the assignment of the entire patent portfolio from the University of Melbourne to Clarity, the Company bolsters its strong IP position as it prepares for the next stage of its corporate and commercial development activities.

“The University of Melbourne has been one of the main collaborating institutions with Clarity on many levels, including basic research, early pre-clinical development, intellectual property, grant funding and direct investment,” commented Clarity’s Executive Chairman, Dr Alan Taylor. “The research of Professor Paul Donnelly and his team at the School of Chemistry and Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, has been critical to the successful development and commercialisation of Clarity’s platform SAR Technology.”

Clarity has aggressively pursued the patent protection of the SAR Technology, as well as the radio-imaging and radio-therapeutic agents associated with it in all major international jurisdictions. Broad patent coverage provides strong protection for Clarity’s platform around the world, and the nature of the SAR Technology and the patent strategy allows Clarity to file additional patents with new disease targeting agents in the development pipeline. Clarity’s lead products in development, SARTATE™, SAR-bisPSMA and SAR-Bombesin, are examples of this strategy. With this broad and deep patenting strategy, the Company aims to safeguard its existing products as well as expand the pipeline and sustain its competitive advantage in the area of radiopharmaceuticals.

Professor Moira O’Bryan, Dean of Science at the University of Melbourne commented, “The University of Melbourne is continually focused on its aims of making distinctive contributions to society in research, teaching and learning, and engagement. Our collaboration with Clarity has seen significant benefits already to both organisations, and we look forward to our continued relationship with the Company as it progresses its very exciting ambitions of treating childhood cancer as well as other large cancer indications such as prostate and breast cancers”.

Dr Taylor commented, “The strong relationship between our organisations remains an important part of Clarity as we continue to work together to make Clarity’s story of commercialising great Australian science a success through our pursuit to improve treatment outcomes for children and adults with cancer.”

Read the original release on Clarity Pharmaceutical's website.

About Clarity

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies based on its SAR Technology Platform for the treatment of cancer and other serious diseases in adults and children.

About the University of Melbourne

The University of Melbourne is a world-leading university that has been at the heart of discovery and the cultural fabric of contemporary Australia for over a century. With strong research performance and excellence in learning and teaching, we are consistently ranked amongst the world’s leading universities and are currently ranked number one in Australia and 31 in the world. Our strategic objective is to benefit global communities and society through the transformative impact of education and research.

Media Contact

Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor [at]